NXTS — Nexentis Technologies Inc.
$0.5242-7.55%
Last close: · regular session
After-hours $0.5240 -0.04% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for NXTS in the TickerWise workspace.
Nexentis Technologies Inc., through its subsidiary, develops therapeutics related to cancer and inflammatory metabolic diseases. It operates through two segments, Biotechnology Activity and Renewable Energy Projects. The company's pipeline includes MITOLINE, an algorithm used to perform multiple sequence/ structure pairwise alignments which could then be used for generating a 3D comparative model of potentially all mitochondrial carrier proteins; cloud-based computational chemistry platform; and novel in-vitro screening platforms; and advanced 3D NSCLC tumor spheroid systems.The company was formerly known as N2OFF, Inc. and changed its name to Nexentis Technologies Inc. in February 2026. Nexentis Technologies Inc. was incorporated in 2009 and is headquartered in Ness Ziona, Israel.
Company profile
- Sector: Basic Materials
- Industry: Agricultural Inputs
- Country: IL
- Exchange: NASDAQ Global Market
- Employees: 5
- Website: https://www.nexentistech.com
Latest SEC filings for NXTS
Latest NXTS news
- Nexentis: MitoCareX Bio Expands Computational Biology Capabilities to Advance Disease-Pathway Analysis Read article
- Nexentis: MitoCareX Bio Deploys its Computational Drug Discovery Infrastructure on Google Cloud Read article
- Nexentis Amends Warrants to Support Nasdaq Compliance
- Warrant amendments at Nexentis (NXTS) add no shares upon exercise and do not extend their terms.
- NXTS Forecast — Price Target
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.